JP7274502B2 - 経口投与用エダラボン懸濁剤 - Google Patents

経口投与用エダラボン懸濁剤 Download PDF

Info

Publication number
JP7274502B2
JP7274502B2 JP2020554977A JP2020554977A JP7274502B2 JP 7274502 B2 JP7274502 B2 JP 7274502B2 JP 2020554977 A JP2020554977 A JP 2020554977A JP 2020554977 A JP2020554977 A JP 2020554977A JP 7274502 B2 JP7274502 B2 JP 7274502B2
Authority
JP
Japan
Prior art keywords
edaravone
suspension
particles
dispersant
polyvinyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020554977A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020091036A5 (enExample
JPWO2020091036A1 (ja
Inventor
哲生 羽山
朋弘 高橋
朋幸 大村
昂司 林
宗智 松田
忠 宮澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70463399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7274502(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of JPWO2020091036A1 publication Critical patent/JPWO2020091036A1/ja
Publication of JPWO2020091036A5 publication Critical patent/JPWO2020091036A5/ja
Priority to JP2023075654A priority Critical patent/JP7828317B2/ja
Application granted granted Critical
Publication of JP7274502B2 publication Critical patent/JP7274502B2/ja
Priority to JP2025168147A priority patent/JP2026010001A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020554977A 2018-11-02 2019-11-01 経口投与用エダラボン懸濁剤 Active JP7274502B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023075654A JP7828317B2 (ja) 2018-11-02 2023-05-01 経口投与用エダラボン懸濁剤
JP2025168147A JP2026010001A (ja) 2018-11-02 2025-10-06 経口投与用エダラボン懸濁剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018207646 2018-11-02
JP2018207646 2018-11-02
PCT/JP2019/043013 WO2020091036A1 (ja) 2018-11-02 2019-11-01 経口投与用エダラボン懸濁剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023075654A Division JP7828317B2 (ja) 2018-11-02 2023-05-01 経口投与用エダラボン懸濁剤

Publications (3)

Publication Number Publication Date
JPWO2020091036A1 JPWO2020091036A1 (ja) 2021-09-24
JPWO2020091036A5 JPWO2020091036A5 (enExample) 2022-11-09
JP7274502B2 true JP7274502B2 (ja) 2023-05-16

Family

ID=70463399

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020554977A Active JP7274502B2 (ja) 2018-11-02 2019-11-01 経口投与用エダラボン懸濁剤
JP2023075654A Active JP7828317B2 (ja) 2018-11-02 2023-05-01 経口投与用エダラボン懸濁剤
JP2025168147A Pending JP2026010001A (ja) 2018-11-02 2025-10-06 経口投与用エダラボン懸濁剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023075654A Active JP7828317B2 (ja) 2018-11-02 2023-05-01 経口投与用エダラボン懸濁剤
JP2025168147A Pending JP2026010001A (ja) 2018-11-02 2025-10-06 経口投与用エダラボン懸濁剤

Country Status (19)

Country Link
US (5) US10987341B2 (enExample)
EP (2) EP3875085B1 (enExample)
JP (3) JP7274502B2 (enExample)
KR (1) KR20210087490A (enExample)
CN (4) CN117398346A (enExample)
AR (1) AR116967A1 (enExample)
AU (2) AU2019369843A1 (enExample)
BR (1) BR112021008197A2 (enExample)
DK (1) DK3875085T3 (enExample)
ES (1) ES2991523T3 (enExample)
FI (1) FI3875085T3 (enExample)
HU (1) HUE068117T2 (enExample)
IL (2) IL319280A (enExample)
MX (3) MX2021005144A (enExample)
PH (1) PH12021550988A1 (enExample)
PL (1) PL3875085T3 (enExample)
PT (1) PT3875085T (enExample)
SG (1) SG11202104365QA (enExample)
WO (1) WO2020091036A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023087011A (ja) * 2018-11-02 2023-06-22 田辺三菱製薬株式会社 経口投与用エダラボン懸濁剤

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019167178A1 (ja) 2018-02-28 2019-09-06 田辺三菱製薬株式会社 ３－メチル－１－フェニル－２－ピラゾリン－５－オン原薬の分析方法、筋萎縮性側索硬化症の治療および筋萎縮性側索硬化症の進行抑制、ならびに、３－メチル－１－フェニル－２－ピラゾリン－５－オン原薬を含む薬剤の製造方法
US11826352B2 (en) 2018-11-02 2023-11-28 Mitsubishi Tanabe Pharma Corporation Edaravone suspension for oral administration
EP3989968A4 (en) * 2019-07-18 2023-07-12 BDR Pharmaceuticals International Private Limited ORAL FORMULATIONS OF EDARAVON AND PROCESSES FOR THEIR PREPARATION
US12194025B2 (en) 2020-11-12 2025-01-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition for oral administration of edaravone and method of administering same
CA3198014A1 (en) 2020-11-12 2022-05-19 Hidetoshi Shimizu Pharmaceutical composition for oral administration of edaravone and method of administering same
GB202103807D0 (en) 2021-03-18 2021-05-05 Johnson Matthey Plc A crystalline salt of edaravone, processes for the preparation and use thereof
JPWO2023149539A1 (enExample) 2022-02-03 2023-08-10
WO2024005187A1 (ja) 2022-07-01 2024-01-04 田辺三菱製薬株式会社 組成物、およびエダラボンの応答可能性の評価方法
US12343330B2 (en) 2023-02-16 2025-07-01 Slayback Pharma Llc Stable pharmaceutical compositions of edaravone
CN118178328A (zh) * 2024-03-21 2024-06-14 药云(西安)医药技术有限公司 依达拉奉包埋物制备方法与其口服制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004091441A (ja) 2002-09-04 2004-03-25 Mitsubishi Pharma Corp ピラゾロン誘導体を含有する経口投与製剤
JP2012056950A (ja) 2010-08-12 2012-03-22 Nisshin Kasei Kk 可溶化剤
JP2014177415A (ja) 2013-03-13 2014-09-25 Daido Kasei Kogyo Kk ナノ粒子化製剤及びその製造方法
WO2018133957A1 (en) 2017-01-17 2018-07-26 Treeway Tw001 B.V. Medical treatment comprising enteral administration of edaravone

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263917A (ja) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk 脳機能正常化剤
JPH07121861B2 (ja) 1986-11-25 1995-12-25 三菱化学株式会社 ３−メチル−１−フエニル−２−ピラゾロン−５−オンを含有する安定な注射剤
JPH0531523A (ja) 1991-07-26 1993-02-09 Aichi Steel Works Ltd ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
JPH1120463A (ja) 1997-06-30 1999-01-26 Zexel Corp 車両用デュアルエアコン
WO2002034264A1 (en) 2000-10-24 2002-05-02 Mitsubishi Pharma Corporation Remedies for amyotrophic lateral sclerosis (als)
US20080161378A1 (en) 2004-02-09 2008-07-03 Hiide Yoshino Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) or Diseases Caused by Als
CN102824356A (zh) 2012-09-25 2012-12-19 江西中医学院 一种黄芩苷纳晶混悬剂、纳晶干粉及其制备方法
WO2014134243A1 (en) 2013-02-27 2014-09-04 Regents Of The University Of Michigan Pharmaceutical compounds and use of same in cancer and tauopathies
CN105878171A (zh) * 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
EP3247334A1 (en) 2015-01-20 2017-11-29 Merck Patent GmbH Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer
JP7026609B2 (ja) * 2016-03-10 2022-02-28 大日本住友製薬株式会社 微細粒子含有組成物およびその製法
CN113768879A (zh) * 2016-03-16 2021-12-10 苏州澳宗生物科技有限公司 依达拉奉剂型
PL3551181T3 (pl) 2017-01-17 2021-05-31 Treeway Tw001 B.V. Leczenie obejmujące doustne lub dożołądkowe podawanie edarawonu
CA3069048A1 (en) * 2017-07-06 2019-01-10 Treeway Tw001 B.V. Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders
MX2021005144A (es) * 2018-11-02 2021-07-15 Mitsubishi Tanabe Pharma Corp Suspension de edaravona para administracion oral.
EP3989968A4 (en) * 2019-07-18 2023-07-12 BDR Pharmaceuticals International Private Limited ORAL FORMULATIONS OF EDARAVON AND PROCESSES FOR THEIR PREPARATION

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004091441A (ja) 2002-09-04 2004-03-25 Mitsubishi Pharma Corp ピラゾロン誘導体を含有する経口投与製剤
JP2012056950A (ja) 2010-08-12 2012-03-22 Nisshin Kasei Kk 可溶化剤
JP2014177415A (ja) 2013-03-13 2014-09-25 Daido Kasei Kogyo Kk ナノ粒子化製剤及びその製造方法
WO2018133957A1 (en) 2017-01-17 2018-07-26 Treeway Tw001 B.V. Medical treatment comprising enteral administration of edaravone

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI Hao et al.，Phase I clinical study of edaravone in healthy Chinese volunteers，Drugs R D，2012年，12(2)、65-70
PARIKH Ankit et al.，Development of a novel oral delivery system of edaravone for enhancing bioavailability，International Journal of Pharmaceutics，2016年，515(1)，490-500，第４９３頁左欄
PARIKH Ankit et al.，Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in viv，Drug Deliv，2017年，24(1), 962-978

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023087011A (ja) * 2018-11-02 2023-06-22 田辺三菱製薬株式会社 経口投与用エダラボン懸濁剤
JP7828317B2 (ja) 2018-11-02 2026-03-11 田辺ファーマ株式会社 経口投与用エダラボン懸濁剤

Also Published As

Publication number Publication date
EP3875085B1 (en) 2024-06-19
CN117379369A (zh) 2024-01-12
US10987341B2 (en) 2021-04-27
PL3875085T3 (pl) 2024-10-21
AU2025205635A1 (en) 2025-08-07
US20220110915A1 (en) 2022-04-14
JP7828317B2 (ja) 2026-03-11
EP3875085A1 (en) 2021-09-08
MX2023009973A (es) 2023-09-06
HUE068117T2 (hu) 2024-12-28
AU2019369843A2 (en) 2023-02-02
DK3875085T3 (da) 2024-07-08
KR20210087490A (ko) 2021-07-12
BR112021008197A2 (pt) 2021-08-03
PH12021550988A1 (en) 2021-10-04
CN112969459B (zh) 2023-12-05
IL282773A (en) 2021-06-30
CN117379370A (zh) 2024-01-12
US11957660B2 (en) 2024-04-16
AU2019369843A1 (en) 2021-05-27
WO2020091036A1 (ja) 2020-05-07
TW202031256A (zh) 2020-09-01
US11241416B2 (en) 2022-02-08
CN117398346A (zh) 2024-01-16
JP2026010001A (ja) 2026-01-21
JPWO2020091036A1 (ja) 2021-09-24
ES2991523T3 (es) 2024-12-03
FI3875085T3 (fi) 2024-08-06
US20240226064A1 (en) 2024-07-11
US12599586B2 (en) 2026-04-14
EP4420724A2 (en) 2024-08-28
US11478450B2 (en) 2022-10-25
US20230030285A1 (en) 2023-02-02
US20210212990A1 (en) 2021-07-15
EP3875085A4 (en) 2022-07-27
EP4420724A3 (en) 2024-11-27
MX2021005144A (es) 2021-07-15
US20200268712A1 (en) 2020-08-27
JP2023087011A (ja) 2023-06-22
CN112969459A (zh) 2021-06-15
IL282773B2 (en) 2025-08-01
PT3875085T (pt) 2024-08-09
IL319280A (en) 2025-04-01
IL282773B1 (en) 2025-04-01
MX2024000663A (es) 2024-01-31
AR116967A1 (es) 2021-06-30
SG11202104365QA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
JP7828317B2 (ja) 経口投与用エダラボン懸濁剤
JP6092629B2 (ja) リファキシミン使用準備済懸濁液
US20250235430A1 (en) Edaravone suspension for oral administration
RU2810789C2 (ru) Суспензия эдаравона для перорального введения
TWI924629B (zh) 經口投予用依達拉奉(Edaravone)懸浮劑
HK40113279A (en) Edaravone suspension for oral administration
BR122024020124A2 (pt) Suspensão de edaravone para administração oral, kit para a preparação da mesma, agente terapêutico para a ela, e seus usos
HK40053006A (en) Edaravone suspension for oral administration
WO2026028170A1 (en) Pharmaceutical composition of edaravone
HK40053006B (zh) 用於口服给药的依达拉奉混悬剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221031

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230329

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230501

R150 Certificate of patent or registration of utility model

Ref document number: 7274502

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

SG99 Written request for registration of restore

Free format text: JAPANESE INTERMEDIATE CODE: R316G99

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S803 Written request for registration of cancellation of provisional registration

Free format text: JAPANESE INTERMEDIATE CODE: R316803

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250